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SwitchingIn this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizo-
phrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were ex-
plored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful
treatment with oral antipsychotics. This pragmatic study was conducted in a large, more representative sample
of the general schizophrenia population compared to randomized controlled pivotal trials, to speciﬁcally mimic
real-world clinical situations. After initiation on Day 1 and Day 8, patients received PP once monthly at ﬂexible
doses (50–150mg eq.) intramuscularly. The primary efﬁcacy outcomewas deﬁned as the percentage of patients
achieving ≥30% improvement in PANSS total score from baseline (BL) to last-observation-carried-forward
(LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale
(ESRS) total score and treatment-emergent adverse events (TEAEs). Overall, 212 patients received PP at least
once after switching from oral antipsychotics, primarily due to lack of efﬁcacy (45.8%). Signiﬁcant improvements
from BL in mean (SD) PANSS total score were observed from Day 8 onwards (BL to LOCF EP:−31.0 [29.0];
p b 0.0001). At endpoint, two-thirds (66.7%) and 43.5% of patients achieved a≥30% and≥50% improvement
inmean PANSS total score, respectively. PPwas associatedwith signiﬁcant improvements across secondarymea-
sures of symptomseverity, subjectivewell-being,medication satisfaction, illness-relateddisorders of activity and
participation, and patient functioning (p b 0.0001; BL to LOCF EP). PP was generally well tolerated, with signiﬁ-
cant reductions in ESRS total score (p b 0.0001) and mainly mild-to-moderate TEAEs. TEAEs reported in≥5% of
patients were injection-site pain (13.7%), insomnia (10.8%), psychotic disorder (10.4%), headache and anxiety
(both 6.1%). The PALMFlexS study ﬁndings provide valuable pragmatic clinical data on PP treatment in patients
with acute schizophrenia previously unsuccessfully treated with oral antipsychotics.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
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Many people with schizophrenia have the potential to achieve long-
term remission and functional recovery (Zipursky et al., 2013), but only
a small proportion realize this goal (Kane, 2013). One study of previous-
ly stabilized patients reported remission rates of 39.2% before relapse
and 35.9% post-relapse (Emsley et al., 2012), while a recent
metaanalysis of 50 studies highlighted that only 13.5% of patients met
recovery criteria (Jaaskelainen et al., 2013).
Although a ﬁrst step towards achieving remission is to elicit a re-
sponse to treatment and bring symptoms under control following an
acute psychotic episode, this goal is frequently disrupted by relapse,
often leading to rehospitalization, poor treatment response and loss of
functional gains (Kane, 2013). The response to antipsychotic treatment
after relapse varies, with a subset of patients displaying emergent re-
fractoriness, independent of the relapse event (ie ﬁrst or subsequent re-
lapse). Furthermore, this trajectory is unaltered even when the interval
betweenﬁrst signs of relapse and initiation of treatment is brief (Emsley
et al., 2013a). In addition, an earlier 15-year prospective follow-up of a
Dutch cohort of patients with schizophrenia found that, following a
relapse, one in six patients did not subsequently respond to treatment
and one in ten committed suicide, supporting the need for adequate
relapse prevention (Wiersma et al., 1998). Recurrent relapse may also
be associated with structural brain changes, cognitive deterioration,
reduced quality of life and overall poor prognosis (Andreasen et al.,
2013; Taylor et al., 2005; van Haren et al., 2007).
Relapses and acute exacerbations in patients with schizophrenia are
common (Emsley et al., 2013b). Notably, a relapse rate of 27% over 7–12
months was reported in a recent metaanalysis of randomized clinical
trials of patients continuing antipsychotic medication after stabilization
(Leucht et al., 2012).Many patients relapse soon after treatment discon-
tinuation, sometimes with the transition from remission to relapse
being abrupt and occurring without warning (Emsley et al., 2013b),
suggesting efﬁcient relapse prevention strategies after initial disease
onset may convey a signiﬁcant clinical beneﬁt (Andreasen et al.,
2013). The most frequent reason for relapse is discontinuation of oral
antipsychotic treatment, with the risk of relapse beingﬁve times greater
among those patients who discontinue their treatment (Robinson et al.,
1999), which is highly relevant given, for example, that less than half of
patients were found to adhere to their initial antipsychotic treatment
during the ﬁrst 30 days after discharge from their ﬁrst hospitalization
for schizophrenia (Tiihonen et al., 2011). Moreover, it has been shown
that healthcare providers consistently overestimate patient adherence
to antipsychotic medication (Byerly et al., 2012).
Long-acting injectable antipsychotic therapy (LAT) has been shown
to reduce relapse rates signiﬁcantly (Kishimoto et al., 2013; Leucht et al.,
2012), and may enhance adherence to treatment in patients with
schizophrenia (Cañas et al., 2013). However, LAT use has generally
been reserved for patients with difﬁculties in complying with oral regi-
mens during maintenance treatment (Ascher-Svanum et al., 2009;
Heres et al., 2006) and their use in the acute hospital setting has largely
been avoided due to their slow-release proﬁles and delayed onset of ef-
fect. Therefore, little is known about use of LATs in patients with acute
symptoms of schizophrenia compared with stabilized patients (Burns,
2009). Given the frequency and early onset of medication non-
adherence among patients with schizophrenia (Tiihonen et al., 2011;
Velligan et al., 2009) and the role of LATs in addressing this problem
as well as in improving broader patient outcomes (Kaplan et al.,
2013), evaluation of the impact of LATs during an acute exacerbation
of schizophrenia is warranted.
Paliperidonepalmitate (PP) is an LAT, designed for once-monthly in-
tramuscular (IM) administration for the maintenance treatment of
schizophrenia (Xeplion SmPC, 2013). PP has been developed as an
aqueous suspension that can be delivered intramuscularly and which
has pharmacokinetic properties that facilitate rapid achievement of
therapeutic plasma concentrations (Meyer, 2013). Using the initiationregimen of PP (150 mg eq. on Day 1 and 100 mg eq. on Day 8, both
administered into the deltoid muscle), an early onset of effect was
observed as of Day 8 of treatment (Pandina et al., 2010) and even
from Day 4, in markedly to severely ill patients (Alphs et al., 2011).
The efﬁcacy of PP in the acute treatment of schizophrenia has been dem-
onstrated in ﬁxed-dose short-term trials (Alphs et al., 2011; Pandina
et al., 2010); however, information and guidance on ﬂexible dosing,
dose–response relationships, strategies for direct transition from other
antipsychotics to PP and use of relevant concomitantmedication in rou-
tine clinical practice are lacking. The pivotal studies for PP in patients
with an acute exacerbation of schizophrenia included an initialwashout
period, usedﬁxed doses (without the option of dosage adjustment), and
were conducted in selected, relatively homogenous groups of patients
(Gopal et al., 2010; Nasrallah et al., 2010; Pandina et al., 2010). There-
fore, there is a need to assess PP in a less restrictive setting, such as a
more diverse population of patients, with higher rates of comorbidities,
substance abuse and/or comedications, to better reﬂect those normally
seen in daily clinical practice.
The Paliperidone Palmitate Flexible Dosing in Schizophrenia
(PALMFlexS) trial is a pragmatic prospective interventional study that
was conducted in a large, more representative sample of patients with
schizophrenia (Schreiner et al., 2014) and was designed to explore
how treatment outcomes may guide recommendations for use of, and
transition to, PP in acutely ill patients with schizophrenia.
2. Materials and methods
2.1. Study design
This was a non-randomized, single-arm, multicentre, open-label, 6-
month, prospective interventional study in patients with acute schizo-
phrenia previously unsuccessfully treated with oral antipsychotics
(Clinical trials.gov number: NCT01281527). A total of 160 sites in 21
countries took part in the study (see Appendix). Prior to trial initiation,
the protocol was reviewed and approved by an independent ethics
committee in all participating countries. The trial was performed in ac-
cordancewith theDeclaration of Helsinki. Patientswere informed of the
risks and beneﬁts of the trial and written informed consent was obtain-
ed before commencement of any trial-related activities.
The study consisted of a screening period, a 6-month study period,
and an optional extension phase. This manuscript reports results from
the 6-month study period. The screening period included a 2-day oral
tolerability test with paliperidone ER for patients without source
documentation of previous risperidone or paliperidone exposure. Only
patients demonstrating an ability to tolerate the drug, as judged by
the treating physician, were eligible to enter the 6-month study period.
The start of the 6-month study periodwas deﬁned as the day of the ﬁrst
PP injection.
2.2. Patients
Eligible participants were males and females aged ≥18 years, with
acute symptoms of schizophrenia (Diagnostic and Statistical Manual
of Mental Disorder [DSM]-IV), deﬁned as having a baseline [BL] Positive
and Negative Syndrome Scale [PANSS] total score of≥80 and a BL Clin-
ical Global Impression— Severity [CGI-S] score of≥4, andwhohad been
previously unsuccessfully treated with an oral antipsychotic in the 4
weeks prior to enrolment. Prior treatment was considered to have
been unsuccessful due to one or more of the following: lack of efﬁcacy
(BL PANSS ≥70 or ≥2 items scoring ≥4 in the PANSS positive or
negative subscale or≥3 items scoring≥4 in the PANSS general psycho-
pathology subscale, as judged by the investigator), lack of tolerability or
safety (the presence of clinically relevant side effects), lack of compli-
ance, or the patient's wish. Additionally, patients were eligible, if, at
the discretion of the investigator, the patient may beneﬁt from a switch
of oral antipsychotic medication to PP.
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substance or a general medical condition; a history of or current symp-
toms of tardive dyskinesia or neuroleptic malignant syndrome; or
known allergies, hypersensitivity, or intolerance to risperidone or
paliperidone or its excipients led to study exclusion. Patients who
were antipsychotic treatment-naïve; receiving clozapine during the
last 3 months prior to the start of the study; or considered to be at
imminent risk of suicide were also excluded from the study, as were
pregnant and breast-feeding female patients. Patients with a current
substance use or abuse, with the exception of intravenous drug use,
were eligible for enrolment and there were no exclusions based on
body mass index (BMI).
2.3. Treatment
At initiation of PP, patients were tapered off their previous oral anti-
psychotic, preferably within a maximum of 4 weeks. PP was initiated at
150mg eq. on Day 1 and 100mg eq. on Day 8 (±2 days) IM, both given
in the deltoidmuscle. Subsequently, PPwas administered oncemonthly
in either the gluteal or deltoid muscle, on Days 38, 68, 98, 128 and 158
(±7 days) using ﬂexible dosages, within the range of 50–150 mg eq.,
based upon the treating physician's clinical judgment of efﬁcacy and
tolerability.
Antipsychotics and other psychotropic medications that were ad-
ministered prior to the start of the study for reasons other than the dis-
ease itself (e.g. sleep induction or sedation) could be continued during
the study at a stable dose at the discretion of the treating physician. In
the event of exacerbation of psychotic symptoms between visits requir-
ing immediate intervention, oral antipsychotic medication, preferably
paliperidone ER, could be givenwithin the approved dose range. Benzo-
diazepines that were newly initiated during the study were allowed as
rescuemedication. The investigators re-evaluated the need for concom-
itant oral antipsychotic treatment, benzodiazepines and anticholinergic
medication on an ongoing basis.
2.4. Efﬁcacy assessments
The primary efﬁcacy outcomewas thepercentage of patients achiev-
ing treatment response, deﬁned as ≥30% improvement in PANSS total
score from BL (Day 1) to last-observation-carried-forward (LOCF) end-
point (EP) (at 6 months or early discontinuation). PANSS was rated and
scored by a trained and qualiﬁed rater (Kay et al., 1987).
Secondary outcomes included PANSS subscale and Marder factor
scores (Marder et al., 1997), CGI-S score, Clinical Global Impression —
Change (CGI-C) score, Personal and Social Performance (PSP) total
score (range 0–100) and four PSP domain scores: socially usefulFig. 1. Patient disposition. *The ITT population encompasses all patients who received at least on
protocol inclusion criteria. ITT, intent-to-treat.activities, personal and social relationships, self-care, and disturbing
and aggressive behavior, each rated on a 6-point scale (Morosini et al.,
2000). The Mini-ICF (International Classiﬁcation of Functionality,
Disability and Health) rating for Activity and Participation Disorders in
Psychological Illnesses (Mini-ICF-APP [Linden and Baron, 2005; Baron
and Linden, 2009; Moldynski et al., 2013]) was used to quantify pa-
tients' abilities and disabilities on 13 dimensions on a 5-point scale
and a total score that was calculated as the sum of the 13 dimension
scores.
Additional secondary outcome measures encompassed the Sub-
jective Well-being under Neuroleptics-Scale (SWN-S) (short form)
(Naber et al., 2001); patient and physician satisfaction with the anti-
psychoticmedication, as assessed using the 14-itemTreatment Satisfac-
tion Questionnaire for Medication (TSQM) scale (Atkinson et al., 2004)
and a 7-point categorical scale, respectively; quality of sleep and
daytime drowsiness, using an 11-point categorical rating scale; and
carer burden, measured according to the Involvement Evaluation
Questionnaire [IEQ] (van Wijngaarden et al., 2000).
2.5. Safety and tolerability
Evaluation of safety and tolerability included the measurement of
extrapyramidal motor symptoms (EPMS) according to Extrapyramidal
Symptom Rating Scale (ESRS) total score (Chouinard and Margolese,
2005) and adverse events (AEs), reported either directly by the patient
or indirectly obtained by means of interviewing patients at study visits.
All reported AEs were coded using theMedical Dictionary for Regulato-
ry Activities (MedDRA version 13.0). Treatment-emergent adverse
events (TEAEs) were deﬁned as AEs that were new in onset or were ag-
gravated in severity following initiation of PP. Recording of bodyweight
and calculation of BMI were also performed. As this was a pragmatic
study reﬂecting routine clinical practice, and data on prolactin plasma
levels with PP have been extensively collected (in N3000 patients) dur-
ing the clinical development program (Gopal et al., 2010; Nasrallah
et al., 2010; Pandina et al., 2010), no regular laboratory tests were con-
ducted in this study; however, investigators could measure laboratory
values, including prolactin, at their own discretion at any time through-
out the study.
2.6. Data analysis
The sample size estimation for patients with acute symptoms of
schizophrenia switched from oral antipsychotics was based on the pri-
mary endpoint for this group. The proportion of patients with at least
30% improvement in PANSS total score was expected to be 40%. Using
the large sample normal approximation, it was estimated at least 93e dose of PP; this includes two patients with a baseline CGI-S score of 3, thus violating the
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gle proportion that maximally extends 10% from the observed
proportion.
Efﬁcacy analyses were undertaken in the intent-to-treat (ITT) popu-
lation, which comprised all patients who received PP at least once, and
had at least one post-BL efﬁcacy assessment. Actual values and changes
from BL were summarized descriptively at each assessment time point
and at the patient's last evaluation (LOCF EP).Moreover, categorical var-
iables were summarized with frequency and percentage. For secondary
efﬁcacy assessments, the change from BL at each visit and at LOCF EP
was analyzed using the Wilcoxon signed-rank test.
Tolerability and safety data, evaluated throughout the study on the
safety ITT population, were summarized descriptively.Table 1
Patient demographics and dosing information.
Characteristic N = 212
Mean age, years (SD) 36.4
(12.1)
Sex
Male, % 59.0
Female, % 41.0
Type of schizophrenia, n (%)
Paranoid 181
(85.4)
Disorganized 13 (6.1)
Catatonic 1 (0.5)
Undifferentiated 11 (5.2)
Residual 6 (2.8)
Baseline weight, kg (SD) 78.9
(18.7)
Baseline body mass index, kg/m2 (SD) 27.3 (6.4)
Patients with ≥1 comorbidity, n (%)⁎ 139
(65.6)
Body systems for which patients (≥10%) report ≥1 comorbidity, n (%)
Psychiatric disorders 47 (22.2)
Nervous system disorders 36 (17.0)
Metabolism and nutrition disorders 28 (13.2)
Number of previous hospitalizations, n (%)
None 36 (17.0)
1 41 (19.3)
≥2 135
(63.7)
PP dosage
Patients receiving PP initiation regimen at Day 1 and Day 8
according to protocol,† n (%)
197
(92.9)
Mean modal PP maintenance dose mg eq. (SD)‡ 107.7
(34.0)
Last PP maintenance dose received, n (%)§
50 mg eq. 17 (9.3)
75 mg eq. 42 (23.1)
100 mg eq. 47 (25.8)
150 mg eq. 76 (41.8)
Relevant concomitant medications
Number (%) of patients using benzodiazepines
At baseline 80 (37.7)
Newly-initiated during study 83 (39.2)
At LOCF endpoint 74 (34.9)
At 6 months for completers¶ 38 (25.5)
Number (%) of patients using anticholinergics
At baseline 27 (12.7)
Newly-initiated during study 24 (11.3)
At LOCF endpoint 18 (8.5)
At 6 months for completers¶ 10 (6.7)
CGI-S, Clinical Global Impression — Severity; PP, paliperidone palmitate; PANSS, Positive
and Negative Syndrome Scale; SD, standard deviation.
⁎Individual patients can be labeled for N1 comorbidity.
†The recommended initiation regimen was PP 150 mg eq. on Day 1 and 100 mg eq. on
Day 8 given in the deltoid muscle.
‡Excluding the initiation regimen (Day 1/Day 8).
§Last dose received by those patients who received the third dose (Month 1) onwards,
n = 182.
¶Completers at 6 months n = 149.3. Results
3.1. Demographics and patient disposition
Patient disposition is described in Fig. 1. A total of 212 patients
received at least one dose of PP (ITT population). The main reason for
transition from prior oral antipsychotic treatment to PP was lack of efﬁ-
cacy (97/212, 45.8%), followed by lack of compliance (74/212, 34.9%).
Baseline characteristics of the patient population are described in
Table 1. Patients were predominantly male (59%) and most had a para-
noid schizophrenia subtype diagnosis (85%). At BL 93 (43.9%) patients
were hospitalized and 69.8% (n = 148) received at least one concomi-
tant medication prior to enrolment.
Mean time on PP treatment was 136.9 days at a mean modal PP
maintenance dose of 107.7 ± 34.0 mg eq. (Table 1). Nearly all patients
(92.9%) received PP according to the recommended initiation regimen
on Day 1 and Day 8. The majority of patients (n = 75, 41.4%) received
100 mg eq. for the third dose (50 mg eq.: n = 6 [3.3%], 75 mg eq.:
n = 44 [24.3%], 150 mg eq.: n = 56 [30.9%]). From the third dose
(Month 1) onwards, 33.0% of the patients had ≥1 dose decrease,
while 34.1% of patients had≥1 dose increase. Themost common reason
for the dose increases was ‘suboptimal efﬁcacy’ (87.7% of the dose
increases after the third dose); the most common reason for the dose
decreases was ‘subject responding well’ (59.5% of the dose decreases
after the third dose).
3.2. Efﬁcacy outcomes
Results for primary and secondary efﬁcacy outcomes are summa-
rized in Table 2. After switching to PP, two-thirds (66.7%) of patients
met the criteria for clinical response (≥30% improvement in mean
PANSS total score) and almost half (43.5%) of patients achieved ≥50%
improvement in mean PANSS total score. Mean PANSS total score was
signiﬁcantly improved (Fig. 2, Table 2), with signiﬁcant reductions
seen as early as Day 8 reﬂecting the ﬁrst post-baseline assessment
(mean reduction from BL [SD]: −9.4 [14.9]; 95% CI −11.4, −7.3;
Wilcoxon signed-rank test, s=−9323.0, df= 199, p b 0.0001). Consis-
tent with the total score, each of the PANSS Positive, Negative and
General Psychopathology subscale and Marder factor scores showed a
signiﬁcant improvement (Supplementary Table 1).
PP was associated with a signiﬁcant decrease in disease severity, as
demonstrated by a reduction in CGI-S score (Wilcoxon signed-rank
test, s =−6575.5, df = 165, p b 0.0001) (Table 2). Moreover, the pro-
portion of patients rated markedly ill or worse based on the CGI-S scale
decreased from 75.1% at BL to 20.5% at LOCF EP (Supplementary Fig. 1).
The majority of patients who switched to PP improved from BL, with
82.1% of patients categorized in CGI-C as minimally (26.5%), much
(41.3%) or very much (14.3%) improved.
Statistically signiﬁcant improvements from BL to LOCF EP were ob-
served inmean SWN-S total score and inmean TSQMglobal satisfaction
score (Table 2). Additionally there were statistically signiﬁcant im-
provements in TSQM satisfaction scores related tomedication effective-
ness (SD) (48.7 [20.2] to 62.0 [23.1]; Wilcoxon signed-rank test,
p b 0.0001) and convenience (59.0 [21.7] to 72.5 [19.4]; Wilcoxon
signed-rank test, p b 0.0001). A trend towards improvement in the
side effects domain scorewas observed, although this did not reach sta-
tistical signiﬁcance (73.3 [32.6] to 79.1 [30.4]; Wilcoxon signed-rank
test, p = 0.0555 [BL to LOCF EP]). A statistically signiﬁcant improve-
ment in physician's satisfaction scores was observed for all aspects of
treatment (Wilcoxon signed-rank test, all p b 0.0001 [BL to LOCF EP]).
3.3. Functioning outcomes
The mean PSP total score increased signiﬁcantly from baseline to
LOCF endpoint (Table 2). Improvement in patient functioning with PP
was also reﬂected in the distribution of PSP category scores, with an
Table 2
Secondary efﬁcacy outcomes⁎.
Baseline (SD) LOCF endpoint (SD) Change from baseline to LOCF endpoint (SD) 95% CI, of mean change p value†
Mean PANSS total score, (n = 207) 98.5 (20.1) 67.4 (24.0) −31.0 (29.0) −35.0,−27.1 b0.0001
Mean CGI-S score, (n = 205) 5.0 (0.8) 3.5 (1.3) −1.5 (1.3) −1.7,−1.3 b0.0001
Mean SWN-S score, (n = 207) 73.8 (15.5) 83.5 (17.9) 9.7 (20.6) 6.6, 12.7 b0.0001
Mean TSQM global satisfaction score, (n = 170) 48.7 (22.4) 61.9 (25.3) 13.2 (30.3) 8.6, 17.7 b0.0001
Mean quality of sleep score, (n = 203)‡ 6.5 (2.6) 7.3 (2.5) 0.8 (3.1) 0.4, 1.2 b0.0001
Mean daytime drowsiness score, (n = 203)§ 4.5 (2.9) 3.0 (2.7) −1.5 (3.6) −2.0,−1.0 b0.0001
Mean PSP total score, (n = 197) 43.9 (15.0) 62.9 (17.1) 19.0 (18.7) 16.4, 21.6 b0.0001
Mini-ICF-APP total score, (n = 207) 26.5 (8.5) 18.5 (9.8) −8.0 (10.4) −9.5,−6.5 b0.0001
CGI-S, Clinical Global Impression— Severity; CI, conﬁdence interval; LOCF, last-observation-carried-forward;Mini-ICF-APP, mini International Classiﬁcation of Functionality, Disability and
Health (ICF) Rating for Activity and Participation Disorders in Psychological Illnesses; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social Performance; SD, standard
deviation; SWN-S, Subjective Well-being under Neuroleptics Scale; TSQM, Treatment Satisfaction Questionnaire for Medication.
⁎Only patients with a baseline measurement and at least one follow-up assessment were included.
†Wilcoxon signed-rank test.
‡A higher score indicates improvements in the quality of sleep.
§A lower score indicates improvements in the level of drowsiness.
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experiencing mild or no functional impairment) from 4.1% at BL to
37.1% at LOCF EP. Following PP treatment, all PSP domain scores showed
a statistically signiﬁcant increase (Wilcoxon signed-rank test, p b 0.0001)
(Supplementary Fig. 2).
Illness-related disorders of activity and participation also im-
proved signiﬁcantly with PP, as measured by Mini-ICF-APP total
scores (Table 2, Supplementary Fig. 3). Additionally,measures of quality
of sleep and daytime drowsiness showed statistically signiﬁcant
improvements (Table 2).
3.4. Tolerability and safety
During the study, 63.7% of patients experienced at least one TEAE.
The majority (89.1%) of TEAEs were rated asmild or moderate in inten-
sity, and did not result in a PP dose change (69.7%). TEAEs reported in
≥5% of patients were injection-site pain (13.7%), insomnia (10.8%),
psychotic disorder (10.4%), headache and anxiety (6.1% each).
Two cases of fatal outcomewere reported, one due to acutemyocar-
dial infarction and one due to completed suicide, both of which were
considered not related to the study drug by the investigator. Overall,
19 (9.0%) patients reported one or more AEs that led to early termina-
tion of the study. The most frequent AEs leading to premature study
discontinuation were psychotic disorder (n = 4, 1.9%), schizophrenia
(n = 2; 0.9%) and amenorrhoea (n = 2; 0.9%).
Among the total patient population, 12 (5.7%) had a potentially
prolactin-related TEAE, two (0.9%) reported hyperprolactinemia, andFig. 2. Change in mean PANSS total score over time. Error bars represent 95% CI. BL,
baseline; CI, conﬁdence interval; LOCF, last observation carried forward; PANSS, Positive
and Negative Syndrome Scale.one (0.5%) patient reported both. Reported potentially prolactin-
related TEAEs included amenorrhoea (2.4%), amenorrhoea, galactorrhea
(0.5%), erectile dysfunction (1.4%), galactorrhea (0.5%), gynecomastia
(0.5%) and sexual dysfunction (1.4%).
ThemeanESRS total score at BLwas 3.8, indicating low levels of EPMS
at the beginning of treatment with PP. Nevertheless there was a statisti-
cally signiﬁcant further reduction in EPMS (ESRS total score 3.8 [6.3] to
2.3 [5.9]; Wilcoxon signed-rank test, p b 0.0001 [BL to LOCF EP]).
A mean (SD) increase of 0.9 (2.0) kg/m2 in BMI was observed in
patients and a mean weight change (SD) between BL and LOCF EP of
2.6 (5.6) kg (95% CI 1.8, 3.4). Overall, 40 (22.5%) patients had a ≥7%
increase in body weight.
4. Discussion
The design of this study permitted optimization of PP and concomi-
tant treatments to meet individual efﬁcacy and tolerability needs of pa-
tients through ﬂexible dosingwithin the recommended dose range. One
advantage of this design is that treatment continuation is potentially
higher than would be achieved otherwise, providing more meaningful
data over a longer treatment period. Moreover, the patient population
of the current sample was considerably different from that utilized in
previously published PP RCTs. Based on inclusion criteria, patients had
higher rates of comorbidities, comedications and substance abuse com-
pared to the RCTs conducted with PP for regulatory purposes (Gopal
et al., 2010; Nasrallah et al., 2010; Pandina et al., 2010). Taken together,
the patient population and ﬂexible-dose design of this study more
closely resemble the situation encountered in routine clinical practice
than that seen in RCTs, which are based on ﬁxed-dose regimens and
more selected patient samples. As such, this study can provide valuable
guidance for use of, and transition to, PP in acutely ill patients with
schizophrenia.
The level of psychotic symptoms experienced by patients at the out-
set of this study is indicative of a patient population with an acute exac-
erbation of schizophrenia, and the results suggest that PP is effective in
improving symptoms of schizophrenia in these patients. Notably,
psychotic symptoms signiﬁcantly improved from Day 8 onwards in
line with the early treatment response seen in other studies with PP
(Alphs et al, 2011; Gopal et al., 2011; Pandina et al, 2010) as well as
other reports suggesting that antipsychotic response starts within the
ﬁrst week of treatment and accumulates over time (Agid et al., 2003;
Kapur et al., 2005; Suzuki et al., 2011). Outcomes particularly important
in acutely ill patients with schizophrenia such as the rapid reduction of
positive symptoms, anxiety, hostility and excitement were also
achieved in this study. These ﬁndings are particularly important in
patients with schizophrenia experiencing an acute exacerbation,
where the primary treatment goal is rapid, optimal control of psychotic
and associated symptoms.
6 L. Hargarter et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 58 (2015) 1–7Paliperidone as a molecule is associated with little or no sedation
(Leucht et al., 2013). In this study of acute patients, there was a high
level of concomitant sedating agent use at BL as well as during the
study. However, the decline in use of concomitant sedating and/or
anxiolytic medication during the study may be associated with the
improvement of psychotic symptoms achieved with PP.
Improving personal and social functioning is another essential com-
ponent of optimizing long-term outcomes for patients with schizophre-
nia. Control of symptoms is important to build a platform for patients to
engage in psychosocial and rehabilitation therapies. However, even
with effective symptom control, deﬁcits in personal and social function-
ing can exist whichmay compromise the patient's capability to function
in everyday life, form relationships and participate in useful activities,
such as employment or school. While the patients' level of functioning
was substantially lower in this acute patient population compared
with non-acute patients switched from oral antipsychotics (Schreiner
et al., 2014), improvements in patient functioning occurred early in
the course of the study. There was a continuous improvement up to
6 months, suggesting that functional improvement is a gradual pro-
cess that requires effective long-term treatment (Schreiner et al.,
2014). In this study the behavioral components of social functioning,
such as social contact and integration as well as patients' abilities and
disabilities relevant for various aspects of functioning also showed
signiﬁcant improvement. These beneﬁts may translate directly or in-
directly into relevant functional outcomes such as employment
(Kozma et al., 2011).
There were no new safety signals related to PP identiﬁed in this
subset of patients and PP was generally well tolerated in line with
earlier trials carried out in acutely exacerbated patients (Gopal
et al., 2010; Nasrallah et al., 2010; Pandina et al., 2010). In random-
ized clinical trials of PP, prolactin levels were measured extensively
at BL and at post-BL assessments; serum prolactin levels were con-
sidered elevated when they exceeded the upper limit of the testing
laboratory's normal range (Einarson et al., 2010). In total, 2831/
3173 (89.2%) patients in 10 clinical trials had prolactin levels record-
ed. Overall, at any time, elevated prolactin levels were found in 38.8%
of patients and potentially prolactin-related AEs were reported in
107/3173 (3.4%) patients. As PALMFlexS was a pragmatic study de-
signed to reﬂect routine clinical practice better, investigators could
assess prolactin serum values at their own discretion at any time
during the study. Potentially prolactin-related TEAEs were assessed
by spontaneous reporting according to standards currently used in
interventional studies. The 5.7% of patients reporting a potentially
prolactin-related TEAE in this patient population was comparable
to that reported in randomized clinical trials and therefore this ap-
proach seems appropriate for assessing the risk of potentially
prolactin-related TEAEs for patients on PP in clinical practice.
While there has been much debate concerning the most appro-
priate means of assessing the relative beneﬁts of LAT versus oral an-
tipsychotics on outcomes in schizophrenia, including relapse
prevention (Kishimoto et al., 2013; Leucht et al., 2011), the results
reported here support the beneﬁts of PP established from RCTs
(Gopal et al., 2010; Nasrallah et al., 2010; Pandina et al., 2010) and
provide supporting evidence for improved outcomes in patients
with acute symptoms of schizophrenia unsuccessfully treated with
oral antipsychotics upon direct switching to PP, in conditions closer
to usual clinical practice. Limitations of the study should also be con-
sidered in interpreting the ﬁndings. As this is a non-comparative
study, conclusions cannot be reached regarding the relative impact
of previous oral antipsychotic treatment on patient outcome follow-
ing switching to PP. The open-label nature of the study may also sub-
ject the results to the potential for bias. In addition, the absence of a
control group may make it more difﬁcult to put the incidence of side
effects into perspective. However, using the same methodology of
collecting TEAEs as in pivotal RCTs in this study allows for the com-
parison of reported side effects.5. Conclusions
The design of this study provides useful data about the clinical
experience of acute and longer-term treatment with PP in patients
with schizophrenia more closely resembling patients encountered
in routine clinical practice, drawing on the investigating physician's
judgment of efﬁcacy and tolerability to assess the most appropriate
dose of PP.
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